Icon Plc ( (ICLR) ) has released its Q4 earnings. Here is a breakdown of the information Icon Plc presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
ICON plc is a Dublin-based global healthcare intelligence and clinical research organization, offering outsourced services to sectors including pharmaceuticals, biotechnology, and public health across 55 countries. In its latest earnings report, ICON plc announced net business wins of $2,413 million for the fourth quarter of 2024, with a book-to-bill ratio of 1.18, and a closing backlog of $24.7 billion. The company reported a slight decrease in quarterly revenue to $2,041.1 million but achieved a full-year revenue growth of 2%, totaling $8,282 million. Key financial metrics highlighted include a 21.5% increase in GAAP net income for the quarter, reaching $260 million, and adjusted net income of $282.4 million. The company also reported a robust free cash flow of $1.1 billion for the year and repurchased $500 million worth of stock. Looking ahead, ICON is reaffirming its financial guidance for 2025, projecting revenue between $8,050 million and $8,650 million and adjusted diluted earnings per share in the range of $13.00 to $15.00.
